Acticor Biotech’s Post

It is with great emotion that we announce today the liquidation proceedings of Acticor Biotech. Despite our efforts to refinance the company, the challenges faced in 2024 have led to this outcome. This decision marks the end of a journey of over 10 years dedicated to innovation in the field of cardiovascular emergencies, particularly with the development of glenzocimab. We have poured all our energy and conviction into the research and development of solutions capable of transforming the management of complex conditions such as ischemic stroke. While recent clinical results did not succeed in convincing investors, we remain confident in glenzocimab’s potential for other indications, such as myocardial infarction. We would like to express our deepest gratitude to all stakeholders who have supported us: employees, shareholders, clinicians, partners, and patients. Your trust and commitment have been the driving force behind this journey. This conclusion does not erase the lessons learned nor the contributions we have made to the scientific community. We hope that these foundations will inspire future projects. Thank you all for these years of collaboration and innovation. ✉️ Letter to shareholders : https://lnkd.in/ehNg7iKu 🔗 Press release link : https://lnkd.in/eajBW_G3

Marc Haddad

Senior Advisor Arkéa Real Estate

4mo

I am sad to have lost my money investing in a stock that I trusted.

Like
Reply
Luc Barraud

Senior Scientist Immunology - Team Manager - Immunotherapies & Transversal studies in oncology and infection diseases.

4mo

Very sad to hear about this new Sophie, I wish you and your team the best for this new year .

Like
Reply
Jérôme MASSOT, PhD

GenAI Cloud Architecture @ Google - Google Pro Data Engineer & ML Engineer & Cloud Architect - Stanford XCS224N - XCS224W - XCS224U

1w

J'ai perdu 13.000€. Ce n'est pas ce que je regrette, car c'est le risque à prendre. Et je pense que le job de recherche scientifique a été sérieux. En revanche, je suis plus dubitatif quant à Anaxago. Mauvaise communication, mauvaise décision, mauvais conseil, impossibilité de céder ses parts de gré à gré, enfin des amateurs quoi. Je ne serais même pas étonné que certains ou certaines de leurs employés et cadres aient même fait des bénéfices sur le corps encore chaud. En un mot première et dernière fois avec eux.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics